Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Feb 16:10:610787.
doi: 10.3389/fonc.2020.610787. eCollection 2020.

Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis

Lin Lai  1   2 , Xinyu Chen  3 , Chuxiao Zhang  1 , Xishan Chen  1 , Li Chen  1 , Ge Tian  1 , Xiaodong Zhu  1   4
Affiliations

Pretreatment Plasma EBV-DNA Load Guides Induction Chemotherapy Followed by Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Cancer: A Meta-Analysis

Lin Lai et al. Front Oncol. .

Abstract

Background: The efficacy of induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in locoregionally advanced nasopharyngeal cancer (LA-NPC) is controversial. In this paper, we conduct a meta-analysis based on relevant studies to provide strong evidence for clinical strategies.

Materials and methods: We searched the MEDLINE, Embase, Cochrane, PubMed, and Web of Science databases for studies that stratified patients based on a high or low plasma Epstein-Barr virus deoxyribonucleic acid (EBV-DNA) load before treatment and compared the clinical efficacy of IC+CCRT vs. CCRT alone in LA-NPC. We tested for heterogeneity of studies and conducted sensitivity analysis. Subgroup analysis was performed for overall survival (OS), progression-free survival (PFS), distant metastasis-free survival (DMFS), and locoregional relapse-free survival (LRFS).

Results: Seven studies with a total of 5289 cases were finally included in the meta-analysis. The heterogeneity test revealed the homogeneity of OS (I 2 = 0.0%, p=0.794), PFS (I 2 = 0.0%, p=0.778), DMFS (I 2 = 0.0%, p=0.997), and LRFS (I 2 = 0.0%, p=0.697) in patients with EBV-DNA loads of ≥4000 copies/ml in both the IC+CCRT and CCRT groups. The results reveal that IC+CCRT significantly extended the OS (HR 0.70 [95% CI 0.58-0.83], p=0.000), PFS (HR 0.83 [95% CI 0.70-0.99], p=0.033), and DMFS (HR 0.79 [95% CI 0.69-0.9], p=0.000) of patients compared with the CCRT group, but there were no beneficial effects on LRFS (HR 1.07 [95% CI 0.80-1.42], p=0.647). The heterogeneity test found that there was no significant heterogeneity of PFS (I 2 = 0.0%, p=0.564), DMFS (I 2 = 0.0%, p=0.648), LRFS (I 2 = 22.3%, p=0.257), and OS (I 2 = 44.6%, p=0.164) in patients with EBV-DNA loads of <4000 copies/ml. The results show that IC+CCRT prolonged DMFS (HR 0.57 [95% CI 0.39-0.85], p=0.006) of patients without significant improvements in OS (HR 0.88 [95% CI 0.55-1.26], p=0.240), PFS (HR 0.98 [95% CI 0.74-1.31], p=0.908), and LRFS (HR 0.98 [95% CI 0.54-1.77], p=0.943).

Conclusions: Pretreatment plasma EBV-DNA can be considered a promising effective marker for the use of IC in LA-NPC patients. The addition of IC could improve the OS and PFS of patients with EBV-DNA load ≥4000 copies/ml, but we saw no efficacy in patients with EBV-DNA load <4000 copies/ml. Moreover, regardless of the EBV-DNA load, IC could improve DMFS, but there was no effect on LRFS.

Keywords: concurrent chemoradiotherapy; induction chemotherapy; locoregionally advanced nasopharyngeal cancer; meta-analysis; pretreatment plasma EBV-DNA load.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of study selection.
Figure 2
Figure 2
Forest plot of overall survival (A), progression-free survival (B), distance metastasis-free survival (C), and locoregional recurrence-free survival (D) between IC+CCRT and CCRT based on EBV-DNA ≥4000 copies/ml or EBV-DNA <4000 copies/ml.
Figure 3
Figure 3
Sensitivity analysis of overall survival (A), progression-free survival (B), distance metastasis-free survival (C), and locoregional recurrence-free survival (D) between IC+CCRT and CCRT based on EBV-DNA ≥4000 copies/ml.
Figure 4
Figure 4
Sensitivity analysis of overall survival (A), progression-free survival (B), distance metastasis-free survival (C), and locoregional recurrence-free survival (D) between IC+CCRT and CCRT based on EBV-DNA <4000 copies/ml.
See this image and copyright information in PMC

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin (2015) 65(2):87–108. 10.3322/caac.21262 - DOI - PubMed
    1. Wei K-R, Zheng R-S, Zhang S-W, Liang Z-H, Li Z-M, Chen W-Q. Nasopharyngeal carcinoma incidence and mortality in China, 2013. Chin J Cancer (2017) 36(1):90. 10.1186/s40880-017-0257-9 - DOI - PMC - PubMed
    1. Hatton OL, Harris-Arnold A, Schaffert S, Krams SM, Martinez OM. The interplay between Epstein-Barr virus and B lymphocytes: implications for infection, immunity, and disease. Immunol Res (2014) 58(2-3):268–76. 10.1007/s12026-014-8496-1 - DOI - PMC - PubMed
    1. Chen Y-P, Chan ATC, Le Q-T, Blanchard P, Sun Y, Ma J. Nasopharyngeal carcinoma. Lancet (2019) 394(10192):64–80. 10.1016/S0140-6736(19)30956-0 - DOI - PubMed
    1. Lo YM, Chan AT, Chan LY, Leung SF, Lam CW, Huang DP, et al. . Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circulating Epstein-Barr virus DNA. Cancer Res (2000) 60(24):6878–81. - PubMed

Publication types

LinkOut - more resources